XML 74 R56.htm IDEA: XBRL DOCUMENT v3.7.0.1
Intangible Assets (Narrative) (Details) - USD ($)
shares in Thousands
 1 Months Ended 12 Months Ended
Oct. 29, 2013
Nov. 30, 2016
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Feb. 28, 2014
Acquired Finite-Lived Intangible Assets [Line Items]            
Other revenue, potential upfront payment related to product sales     $ 4,700,000      
Additions to intangible assets     2,000,226 $ 2,556,465 $ 3,101,565  
Amortization of intangible assets     2,194,039 1,989,264 1,596,689  
Payments to acquire businesses     0 0 $ 2,000,000  
Product and License Rights            
Acquired Finite-Lived Intangible Assets [Line Items]            
Intangible assets, gross     20,543,262 18,011,362    
Patents            
Acquired Finite-Lived Intangible Assets [Line Items]            
Intangible assets, gross     8,844,994 8,236,719    
Additions to intangible assets     $ 600,000 100,000    
Product Rights Agreement, U.S. Commercialization Rights for Kristalose from Inalco Biochemicals, Inc. and Inalco S.p.A. | Product, Kristalose | Product and License Rights            
Acquired Finite-Lived Intangible Assets [Line Items]            
Product rights agreement, quarterly payments, expiration date     7 years      
Quarterly payments made     $ 1,400,000 $ 1,500,000    
Product, Vaprisol | Product and License Rights            
Acquired Finite-Lived Intangible Assets [Line Items]            
Intangible assets, gross           $ 3,000,000
Pernix Therapeutics | Collaborative Arrangement, Amended International Agreement            
Acquired Finite-Lived Intangible Assets [Line Items]            
Other revenue, potential upfront payment related to product sales $ 4,000,000          
Methotrexate            
Acquired Finite-Lived Intangible Assets [Line Items]            
Payments to acquire businesses   $ 100,000        
Liabilities incurred   900,000        
Stock issued during period, acquisitions   $ 990,000        
Restricted Stock | Methotrexate            
Acquired Finite-Lived Intangible Assets [Line Items]            
Stock issued during period, acquisitions (in shares)   180